Former U.S. Senator for Nebraska Ben Sasse (left) and an image of a doctor reviews medical scans for signs of cancer (right).

...

Jasmine Laws

By Jasmine Laws

Reporter

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


Former GOP Senator Ben Sasse of Nebraska who shared at the end of last year he was diagnosed with pancreatic cancer, has credited a new "miracle drug" called daraxonrasib for shrinking his tumor volume by more than three quarters over the last four months in a Sunday interview with CBS News' 60 Minutes.

At the time of his diagnosis, which he wrote in a December 2025 post on X was a "death sentence," he was told he had around three to four months left to live.

"Maybe I'm going to crank and live a year instead of a handful of months, and I'd feel incredibly blessed," the former senator said about the drug in his 60 Minutes interview.

Read More on Health

Pancreatic cancer currently ranks as the third leading cause of cancer-related death in the U.S., trailing only lung and colorectal cancers. This year, an estimated 67,530 Americans will be diagnosed with pancreatic cancer, and 52,740 are expected to die from the disease, according to Pancreatic Cancer Action Network (PCAN).

Former U.S. Senator for Nebraska Ben Sasse and an image of a doctor reviews medical scans for signs of cancer.

...

What Is Daraxonrasib

Daraxonrasib, manufactured by Revolution Medicines, is a drug for patients with rat sarcoma virus (RAS) connected cancers that is currently in Phase 3 clinical trials.

It's the first of its kind, as a drug that inhibits RAS proteins but also addresses "a diverse and broad spectrum of oncogenic RAS drivers," the company said.

RAS is a family of proteins recognized as influencing the development of various kinds of cancer, including non-small-cell lung cancer, colorectal cancer and pancreatic cancer.

Pancreatic cancer is the most RAS-addicted of all major cancers, with more than 90 percent of patients having tumors driven by mutations in RAS proteins, according to Revolution Medicines.

Newsweek has contacted Revolution Medicines via email for comment.

Daraxonrasib Clinical Trials

Earlier this month, Revolution Medicines announced it was seeing positive results from its ongoing global Phase 3 trial, also known as RASolute 302 (NCT06625320), of daraxonrasib.

The oral drug, taken once daily, has been found to generate "statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared with standard of care cytotoxic chemotherapy delivered intravenously," the company said in a press release.

Daraxonrasib was also found to potentially increase life expectancy for patients longer than chemotherapy. Those taking the drug were found to have a median overall survival of 13.2 months, compared to 6.7 months, for those being treated with chemotherapy.

Per Revolution Medicines' press release, daraxonrasib has also been generally "well tolerated, with a manageable safety profile and with no new safety signals."

Those eligible to participate in the study must match select criteria, such as being at least 18 years of age, having a confirmed pancreatic ductal adenocarcinoma diagnosis with metastatic disease and a number of others. The study is taking place across 60 locations within the U.S. and abroad.

What Is Ben Sasse's Illness?

Sasse was diagnosed with advanced pancreatic cancer after he went to the doctor about intense back pain, which was found to be caused by pancreatic tumors pressing against his spine.

He has been taking morphine to relieve the pain, and using daraxonrasib, which he has said has significantly reduced the tumors in his body and reduced his overall pain by around 80 percent.

However, while he deemed the drug a "miracle," he has also described it as "nasty," as it has left him with bleeding skin on his face. In an interview with the New York Times earlier this month, he said the drug has made his skin and face feel “nuclear.”

It's not clear how the drug results in the skin inflammation, and Revolution Medicines did not mention reported side effects like it in its latest update about the clinical trials.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines